Worldwide Clinical Trials

What Worldwide Clinical Trials does

Worldwide Clinical Trials is a global, full-service Contract Research Organization (CRO) headquartered in Morrisville, North Carolina (Research Triangle Park), that provides preclinical through Phase IV clinical development services to pharmaceutical and biotechnology companies. Founded in 1986, the company operates across more than 70 countries with approximately 4,400 professionals following its February 2026 acquisition of oncology-specialist CRO Catalyst Clinical Research. The service portfolio spans the full clinical lifecycle through two primary commercial constructs: Worldwide Flex, a modular offering spanning full-service trial management to functional service partnerships (FSP) across clinical monitoring, data management, biostatistics, pharmacovigilance, medical writing, and regulatory affairs; and a dedicated integrated bioanalytical laboratory capability. Therapeutic depth is concentrated in six primary areas: oncology (with 800+ specialized staff across 12 cancer subspecialties including ADCs, immuno-oncology, hematologic, and early- and late-phase oncology), neuroscience/CNS (Alzheimer's, neurology, pain, psychiatry, psychedelics), rare disease, cell and gene therapy, cardiovascular and metabolic (including MASH/MASLD), and immune-mediated inflammatory diseases.

The company's go-to-market is enterprise field sales-led, with dedicated direct outreach to biopharma sponsors supported by a "Request Proposal" self-service channel and active participation in therapeutic-area conferences. Pricing is quote-based on multi-year contracts with no public list pricing. The firm is privately held and majority-owned by Kohlberg, a private equity firm that acquired Worldwide in August 2023 and subsequently backed the Catalyst acquisition from QHP Capital. Recent strategic priorities include technology differentiation through a first-of-its-kind partnership with Medidata to deploy the Medidata Plus AI platform (including the Dot virtual AI companion) across trial workflows, and a partnership with Every Cure to operationalize clinical trials for AI-identified drug repurposing candidates in rare disease. The company has been recognized as the highest-rated Phase II/III CRO in the 2025 ISR Benchmarking Report and has received CRO Leadership Awards for 11 consecutive years, with project team retention exceeding 90%.

Name

Worldwide Clinical Trials

Legal name

Worldwide Clinical Trials Holdings, Inc.

Website

https://worldwide.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Worldwide Clinical Trials is a global, PE-backed full-service CRO providing Phase I-IV clinical development, bioanalytical, and FSP services across oncology, neuroscience, rare disease, and cell and gene therapy to biopharmaceutical and biotechnology sponsors in 70+ countries.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) / Clinical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Management Consulting Services (8742)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

Keywords

• Contract research organization
• Clinical trial services
• Bioanalytical laboratory services
• Functional service partnerships
• Pharmaceutical clinical development

Headquarters

HQ city

Morrisville

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Full-Service CRO Phase I-IV: Comprehensive clinical trial management services across all development phases from early-phase and first-in-human studies through Phase III registration trials. Services include therapeutic expertise delivery, operational execution, and regulatory support throughout the product development lifecycle.
2. Worldwide Flex Functional Service Partnerships (FSP): Flexible functional service model allowing sponsors to outsource specific operational components while retaining strategic oversight. Provides modular services including clinical monitoring, data management, biostatistics, and patient safety on a functional basis.
3. Bioanalytical Laboratory Services: Integrated bioanalytical laboratory services supporting clinical trial operations with specialized testing capabilities across therapeutic areas.
4. Consulting and Regulatory Services: Strategic consulting services including regulatory affairs, protocol development, feasibility assessment, and quality assurance support for clinical development programs.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Worldwide Clinical Trials is a global full-service Contract Research Organization (CRO) that provides Phase I-IV clinical development services to pharmaceutical and biotechnology companies. Its core offering includes Worldwide Flex, a flexible engagement model spanning full-service trial management to functional service partnerships (FSP), supported by an integrated bioanalytical laboratory and specialized therapeutic expertise across oncology, neuroscience, rare disease, cell and gene therapy, cardiovascular/metabolic, and immune-mediated inflammatory diseases.

Product overview

Worldwide Clinical Trials is a global full-service Contract Research Organization (CRO) offering a comprehensive portfolio of clinical development services. The core offering includes Worldwide Flex, a flexible service model spanning full-service trial management to functional service partnerships, supported by integrated bioanalytical lab services. The company provides end-to-end Phase I-IV clinical trial services across six major therapeutic areas: Oncology (with 12 cancer type subspecialties), Neuroscience (including psychedelics), Immune-Mediated Inflammatory Disease, Cardiovascular & Metabolic, Rare Disease, and Cell & Gene Therapy. Supporting capabilities include consulting, clinical assessment training (CATS), pharmacovigilance, global regulatory affairs, quality assurance, real-world evidence, and trial optimization tools. The portfolio is powered by Medidata AI integration for workflow automation and the Every Cure AI partnership for drug repurposing.

Differentiator

Problem solved

Functional benefit

Products and services

• Worldwide Flex

Quantifiable outcome

• Highest-rated Phase II/III CRO across multiple categories in ISR Benchmarking Report 2025
• +4 more outcomes

Named customers4 records

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• MedidatacoreTechnology or Integration · 23 April 2026Strategic partnership making Worldwide the first global CRO to implement Medidata Plus with full AI layer access across the Medidata Platform. The partnership integrates Medidata's AI capabilities including Dot virtual companion into Worldwide's operations to streamline clinical trial workflows from protocol design through study close-out. Both CEOs stated the collaboration positions Worldwide ahead of traditional market standards and establishes a new model for trial execution.
• Every CurecoreStrategic or Co-development PartnerPartnership to advance rare disease treatments using AI-driven drug repurposing. Every Cure uses AI algorithms to identify drug-disease matches across 60+ million possible combinations, and Worldwide operationalizes clinical trials for prioritized repurposed assets. The partnership enables faster development timelines by leveraging existing data and regulatory pathways for approved drugs in new indications.
• Catalyst Clinical ResearchcoreOthersAcquired oncology specialist CRO based in Nottingham, England. The acquisition closed in Q1 2026 (February 2026). Combined organization employs approximately 4,400 professionals across 70+ countries with expanded capabilities in early-phase oncology, biometrics, and functional service provision. Key executives from Catalyst joined Worldwide's leadership team.
• WCG Avoca Quality ConsortiumminorStrategic or Co-development PartnerWorldwide joined WCG's Avoca Quality Consortium in May 2025 to elevate clinical trial quality through collaboration with other industry partners on quality standards and best practices.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• IQVIA: IQVIA is the world's largest CRO with deep Phase I-IV capabilities, advanced R&D technology, and a global operating footprint spanning biopharma and biotech sponsors. It is the dominant incumbent against which Worldwide competes for large enterprise CRO contracts.
• ICON plc: ICON is a top-three global CRO offering full-service and FSP models across all phases and therapeutic areas, formed in part through its PRA Health Sciences acquisition. Directly comparable to Worldwide's Phase I-IV, FSP, and bioanalytical offerings at a larger scale.
• Labcorp / Fortrea: Fortrea, spun out of Labcorp, is a major Phase I-IV CRO with deep bioanalytical lab heritage and broad therapeutic coverage. It competes head-to-head with Worldwide for full-service and FSP engagements, particularly in late-phase oncology and central lab services.
• Syneos Health: Syneos is a top global CRO now operating as a private company following its take-private, offering full-service clinical development and commercial services. It is a direct competitor to Worldwide across Phase II-IV biopharma and biotech engagements.
• Thermo Fisher Scientific (PPD): Thermo Fisher's PPD clinical research services division is one of the largest global CROs, offering Phase I-IV services across all therapeutic areas. It is a scale-incumbent competitor that competes with Worldwide for large biopharma contracts.

Direct peers

• Medpace Holdings: Medpace is a mid-sized, profitable, therapeutically focused full-service CRO with strong reputation in oncology, metabolic disease, and rare disease — directly comparable to Worldwide's therapeutic specialization strategy and similar size band.
• Parexel International: Parexel is a private-equity-owned global CRO offering Phase I-IV services with strong oncology, rare disease, and CNS expertise. Like Worldwide, it operates as a PE-backed mid-to-large CRO and competes directly for biopharma full-service programs.
• Charles River Laboratories: Charles River is a leading CRO/CDMO with strong early-phase development, discovery, and safety assessment capabilities that overlap with Worldwide's Phase I/Clinical Pharmacology and bioanalytical offerings. Comparable in serving biotech and biopharma sponsors globally.
• PSI CRO: PSI is a privately-held, therapeutically focused full-service CRO with strong oncology and rare disease capabilities serving mid-sized biotech sponsors globally. It directly mirrors Worldwide's mid-tier, therapeutically specialized CRO positioning.

Emerging players

• WuXi AppTec (WuXi Clinical): WuXi AppTec is a leading China-based CRO/CDMO with global clinical operations serving biotech and biopharma sponsors. It is a partial competitor to Worldwide for global clinical trials, particularly for sponsors seeking Asia-Pacific scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/worldwidetrials
• Facebookfacebook.com/worldwideclinicaltrials
• LinkedInlinkedin.com/company/worldwide-clinical-trials-inc-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Worldwide Clinical Trials